Literature DB >> 22048803

Experimental autoimmune myasthenia gravis in the mouse.

Bo Wu1, Elzbieta Goluszko, Ruksana Huda, Erdem Tüzün, Premkumar Christadoss.   

Abstract

Myasthenia gravis (MG) is a T cell-dependent antibody-mediated autoimmune neuromuscular disease. Antibodies to the nicotinic acetylcholine receptor (AChR) destroy the AChR, thus leading to defective neuromuscular transmission of electrical impulse and to muscle weakness. This unit is a practical guide to the induction and evaluation of experimental autoimmune myasthenia gravis (EAMG) in the mouse, the animal model for MG. Protocols are provided for the extraction and purification of AChR from the electric organs of Torpedo californica, or the electric ray. The purified receptor is used as an immunogen to induce autoimmunity to AChR, thus causing EAMG. The defect in neuromuscular transmission can also be measured quantitatively by electromyography. In addition, EAMG is frequently characterized by the presence of serum antibodies to AChR, which are measured by radioimmunoassay and by a marked antibody-mediated reduction in the number of muscle AChRs. AChR extracted from mouse muscle is used in measuring serum antibody levels and for quantifying muscle AChR content. Another hallmark of the disease is complement and IgG deposits located at the neuromuscular junction, which can be visualized by immunofluorescence techniques.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22048803     DOI: 10.1002/0471142735.im1523s95

Source DB:  PubMed          Journal:  Curr Protoc Immunol        ISSN: 1934-3671


  6 in total

1.  Delivery of an miR155 inhibitor by anti-CD20 single-chain antibody into B cells reduces the acetylcholine receptor-specific autoantibodies and ameliorates experimental autoimmune myasthenia gravis.

Authors:  Y-Z Wang; F-F Tian; M Yan; J-M Zhang; Q Liu; J-Y Lu; W-B Zhou; H Yang; J Li
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

2.  Myeloid-derived suppressor cells as a potential therapy for experimental autoimmune myasthenia gravis.

Authors:  Yan Li; Zhidan Tu; Shiguang Qian; John J Fung; Sanford D Markowitz; Linda L Kusner; Henry J Kaminski; Lina Lu; Feng Lin
Journal:  J Immunol       Date:  2014-07-23       Impact factor: 5.422

3.  Engineered agrin attenuates the severity of experimental autoimmune myasthenia gravis.

Authors:  Zhiguo Li; Minshu Li; Kristofer Wood; Steffan Hettwer; Suraj A Muley; Fu-Dong Shi; Qiang Liu; Shafeeq S Ladha
Journal:  Muscle Nerve       Date:  2018-01-08       Impact factor: 3.217

4.  Complement regulatory protein Crry deficiency contributes to the antigen specific recall response in experimental autoimmune myasthenia gravis.

Authors:  Jindrich Soltys; Xiaobo Wu
Journal:  J Inflamm (Lond)       Date:  2012-05-29       Impact factor: 4.981

5.  Histone Deacetylase Isoforms Differentially Modulate Inflammatory and Autoantibody Responses in a Mouse Model of Myasthenia Gravis.

Authors:  Afrin Bahauddin; Maxim Ivannikov; Zhongying Wang; Mohammad Jamaluddin; Kyra Curtis; Naazneen Ibtehaj; Linsey Yeager; Lynn Soong; Xiang Fang; Ruksana Huda
Journal:  Front Neurol       Date:  2022-02-10       Impact factor: 4.003

6.  An adult patient with ocular myasthenia and unusually long spontaneous remission.

Authors:  Jasem Al-Hashel; Hanaa M Rashad; Rossen T Rousseff
Journal:  Case Rep Neurol Med       Date:  2014-04-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.